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Abstract  Chikungunya  virus  (CHIKV)  is a  re-emerging  mosquito  borne  alphavirus  responsible
for the  recent  outbreak  in the  Americas.  Immunologically  naïve  population  in the  Americas
favors the  spread  of epidemics.  Chikungunya  fever  is  characterized  by an  abrupt  febrile  illness,
polyarthralgia  and  maculopapular  rash.  In  chikungunya  fever,  shock  or  severe  hemorrhage  is
very rarely  observed;  the  onset  is more  acute  and  the  duration  of  fever is shorter  than  dengue
disease. The  pain  is much  more  pronounced  and  localized  to  the  joints  and  tendons  in chikun-
gunya  fever,  in comparison  to  dengue  fever.  There  is  no  specific  and  effective  antiviral  therapy
and vaccines  are  still  in  trails.  The  only  effective  preventive  measures  consist  of  individual  pro-
tection against  mosquito  bites  and  vector  control.  Disease  prevention  is  important  due  to  the
economic burden  it  entails.  Clinicians  need  to  distinguish  chikungunya  fever  between  dengue
fever and  other  diseases  to  give a  successful  treatment  and  prevent  disease  spreading.
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Introduction
Chikungunya  fever  is  a viral  disease  transmitted  through  the
bite  of  infected  Aedes  mosquitoes.  The  disease  typically
consists  of  an acute  illness  with  fever,  skin  rash,  and incapac-
itating  arthralgia.  The  word chikungunya  means,  ‘‘to walk
bent  over’’  in  the  African  dialect  Makonde,  and  refers to  the
effect  of  the  incapacitating  arthralgia  seen  in the affected
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patients.1 Chikungunya  virus  (CHIKV)  is  the  etiological  agent
and  a  member  of  the  Alphavirus  genus  in the Togaviridae
family.2
Chikungunya  cases  occur  in  Africa,  Asia  and the  Indian
subcontinent.  Human  infections  in  Africa  have  been  at  rel-
atively  low  levels  for  a  number  of  years.  In  December  2013,
France  reported  2  laboratory-confirmed  autochthonous
cases  of  in the French  part  of the  Caribbean  island  of St
Martin.  Since  then,  local  transmission  has  been  confirmed  in
over  43  countries  and  territories  in the  American  region.3
This  was  the  first  documented  outbreak  of  CHIKV  with
autochthonous  transmission  in  the Americas;  therefore  it is
subject  of  big  concern  in our  continent.
CHIKV  genome, structure and  replication
Chikungunya  virus  is  an enveloped  plus-strand  RNA virus  with
icosahedral  symmetry.  The  virion  is 70  nm  in  diameter  and  it
is  composed  of repeating  units  of  the  E1 and  E2  transmem-
brane  glycoproteins  (240  heterodimers  of  E2/E1  arranged  as
trimeric  spikes  on  its  surface),  the  capsid  (C),  a host-derived
lipid  bilayer,  and  a  single  molecule  of  genome  RNA.4 The
genome  is  approximately  12  kb  in length  and  encodes  the
nonstructural  proteins  (nsPs)  at the  5′ end  and  the struc-
tural  proteins  at  the 3′ end. The  nsPs  are translated  from
genomic  RNA  and  the structural  proteins  from  a subgenomic
RNA  (Fig.  1).5
Alphaviruses  enter  target  cells  by  endocytosis.  A few
receptors  (DC-SIGN,  L-SIGN,  heparin  sulphate,  laminin  and
integrins)  have  been  implicated  in this process,  but  their
precise  roles  have  not  been  clearly  proven.5 Recently,
prohibitin  was  identified  as  CHIKV  receptor  protein.6 Fol-
lowing  endocytosis,  the acidic  environment  of the  endosome
triggers  conformational  changes  in  the  viral  envelope  that
expose  the  E1 peptide,  which  mediates  virus--host  cell  mem-
brane  fusion.  This  allows  cytoplasmic  delivery  of  the  core
and  release  of  the viral  genome.  Two  precursors  of  non-
structural  proteins  are translated  from  the  viral  mRNA,
and  cleavage  of these  precursors  generates  nsP1--nsP4.7
These  proteins  assemble  to  form  the  viral  replication  com-
plex,  which  synthesizes  a  full-length  negative-strand  RNA
intermediate.  This  serves  as  the template  for  the synthe-
sis  of  both  subgenomic  (26S)  and  genomic  (49S)  RNAs.  The
subgenomic  RNA drives the  expression  of the C--pE2--6K--E1
polyprotein  precursor,  which  is  processed  by  autoprotoly-
sis.  The  capsid  is  released,  and  further  processing  generates
the  pE2  and  E1  glycoproteins.  PreE2  and  E1 associate  in the
Golgi  and  are  exported  to  the plasma  membrane,  where  pE2
is  cleaved  into  E2  and E3. Binding  of  the viral  nucleocapsid
to  the  viral  RNA  and  the  recruitment  of the membrane-
associated  envelope  glycoproteins  promote  viral  assembly.
The  assembled  alphavirus  particle,  with  an  icosahedral  core,
buds  at  the  cell  membrane.5,7
Vectors,  transmission and reservoirs
Two  distinct  transmission  cycles  have  been well  docu-
mented:  enzootic  and  urban.  In  Africa,  an enzootic  cycle
occurs  in forested  habitats  where  arboreal  mosquitoes,
principally  Aedes  spp,  serve  as vectors.  Evidence  points
to  nonhuman  primates  as the  principal  reservoir  and
amplification  hosts in the  enzootic  cycle  based  on  their  high
rates  of seroprevalence,  documented  infection  and  viremia
in nature,  and  viremia  levels  in  response  to  experimental
infection.8
The  enzootic  transmission  cycle  can  spill  over to  infect
people  who  live  nearby,  and  enzootic  mosquito  vectors
may  be  involved  in  interhuman  transmission  during  small
outbreaks.  Epidemics  also  occur  in Africa  when CHIKV  is
introduced  into  urban  areas  where  the  more  anthropophilic
vectors,  Aedes  aegypti  and  Aedes  albopictus,  can initiate
human--mosquito--human  transmission.
CHIKV  is  capable  of  initiating  a  sustained,  urban  transmis-
sion  cycle  that relies  only on A.  aegypti  and/or  A. albopictus
and  human  amplification  hosts.9 This  endemic/epidemic
cycle  results  in  high  levels  of  human  exposure  to  mosquito
transmission,  particularly  because  these  vectors  live  in close
proximity  to  people.
The  behavior  and  ecology  of  A. aegypti,  in particular,  are
ideal  for  epidemic  transmission  because  adult females  pre-
fer  to feed  on  humans,  often  take  several  partial  blood  meals
during  a  single  gonotrophic  cycle,  oviposit  in artificial  con-
tainers  as  their  preferred  larval  sites,  and rest  inside  houses
with  ready  access  to  human  hosts.10
A.  albopictus  is  both  zoophilic  and  anthropophilic,
aggressive,  silent,  active  all-day  long,  and  has  a  longer
lifespan  than  other  mosquitoes  (up  to 8  weeks).  In recent
decades  it  has  expanded  to  several  areas  previously  known
to  be Aedes-free.11,12 It  seems  that  most  new introductions
of  A. albopictus  have been  caused  by  vegetative  eggs con-
tained  in  timber  and  tires exported  from  Asia  throughout  the
world.13
Although  the  infectivity  of  various  CHIKV  strains  varies
widely  for  both  A. aegypti  and A. albopictus, humans
develop  high-titer  viremias  that  generally  persist  during
the first  4  days  after  the onset  of  symptoms,  with  the
peak  estimated  on  the  day  of  onset  at approximately
109 viral  RNA copies/ml14 and  infectious  titers  sometimes
exceeding  107 PFU/ml.15 These  titers  generally  exceed  the
oral  infectious  dose  50%  levels  for both  epidemic  vector
species,  permitting  efficient  transmission  among  humans  by
mosquitoes.16
Human  beings  serve as  the main CHIKV  reservoir  during
epidemic  periods.  Outside  these  periods,  monkeys,  rodents,
and  birds  constitute  the virus  reservoir  sustaining  virus  circu-
lation  in  the environment  in  the  absence  of human  cases.17,18
Geographic  distribution
CHIKV  is typically  found  being  transmitted  in  Africa  and
Southeast  Asia. Since its  discovery  in 1952,  CHIKV  has  caused
several  epidemics  in  these  places.19,20
The  last  huge  outbreak  started  in Kenya  in 2004  and
spread  through  neighbor  islands  to  La  Réunion  in 2005.21
After  that,  the virus  spread  to  several  islands  in the Indian
Ocean  and  India.1,22 From India  it spread  to  Sri Lanka,  Thai-
land,  Malaysia  and finally  to Italy  in 2007.23,24 In  2009  CHIKV
transmission  restarted  in La  Réunion  and  lead  to  CHIKV  re-
importation  to  Europe  in May  2010.25
During  2011,  CHIKV  was  transmitted  in Oceania,  Central
Africa,  Southern  and  Southeastern  Asia,  Europe  and  West-
ern  Indian  Ocean  Islands.  In  2012,  CHIKV  was  reported  in:
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Figure  1  Organization  of  the  chikungunya  virus  genome.  The  figure  shows  the  nonstructural  and  structural  proteins  the  way  they
are organized  throughout  the genome  as  well  as  the  non-translatable  regions  in  5′ and  3′. The  function  and  size  in amino  acids
is showed  for  each  protein.  The  figure  is  drawn  to  scale  based  on the  CHIKV  genome  with  GenBank  access  number:  AM258990.
The non-translatable  regions  sizes  were  obtained  from  Hyde  et  al.92 The  figure  was  adapted  from  Weaver61 and  Solignat.93 nsP,
nonstructural  protein;  C, capsid;  E,  envelope;  AA,  amino  acid.
Southeastern,  Southern  and  Western  Asia; Oceania;  Central
and  Western  Africa;  and  Western Indian  Ocean  Islands.  Dur-
ing  2013,  CHIKV  was  transmitted  in Southeastern,  Southern
and  Eastern  Asia and  Oceania.20
The  current  outbreak  started  in,  the Caribbean  Island,
Saint  Martin  on  December  6, 2013.26 During  December
2013  and  January  2014  it spread  to  the neighbor  islands.27
In  February,  it continued  spreading  and reached  French
Guiana.28 In  May,  Guiana  and  almost  all  the Caribbean
Islands  reported  autochthonous  CHIKV  infections.29 In  June,
the  first  cases  of  El Salvador  were  reported.30 By July,
autochthonous  transmission  was  reported  in Florida,  USA,
Costa  Rica,  Panama  and  Venezuela.31 By September,  cases
were  reported  in Guatemala,  Colombia  and  Brazil.32 In Octo-
ber,  Nicaragua  and  Paraguay  reported  cases  for  the  first
time  and  Guatemalan  cases  rose.33 By the end  of Novem-
ber,  Mexico  reported  its first  autochthonous  transmission  in
the  southern  state  of  Chiapas.  Also  by  this  month,  Belize  and
Honduras  reported  cases.34
According  to the  Pan  American  Health  Organization
(PAHO),  since  the  current  outbreak  started,  there  have been
1,280,953  suspected  autochthonous  transmission  cases  and
more  than  26,300  have  been  confirmed  in America.35 The
recent  reports  obtained  from  Mexico  reveals  405 confirmed
autochthonous  transmissions.35 Nevertheless,  this numbers
does  not  include  patients  that did  not look  for medical  aid.
Phylogeny
There  are  four  identified  CHIKV  lineages,  each with  dis-
tinct  genotypic  and  antigenic  characteristics.  The  first
phylogenetic  study  revealed  that  CHIKV  spread  from  Africa
where  two  major lineages  circulated:  West  African  and
East/Central/South  African  (ECSA).  Posteriorly  the  ECSA  lin-
eage  spread  to  Asia  and  originated  the  Asian  lineage.36,37
Until  2004,  these  were  the  only  identified  CHIKV  lineages
that  were  circulating.  The  source  of  the  2005  Indian  Ocean
epidemic  was  traced  to  the ECSA  lineage.38 When  the Indian
Ocean  epidemic  started  in Kenya  2004,  the  first  CHIKV  iso-
lates  from  La  Réunion  epidemic  exhibited  an  alanine  at E1
envelope  protein  residue  226,  but  later  isolates  showed  an
A226V  substitution.  This  and additional  substitutions  gave
rise  to  the  fourth  lineage,  Indian Ocean  lineage.38,39
Pathogenesis
The  pathogenesis  of  CHIKV  infection  in humans  is still
poorly  understood,  but  recent  outbreaks  have  helped
providing  insights  into  the  cells  and  organs  involved  in
viral  replication.  Following  intradermal  inoculation  by
infected  mosquitoes,  CHIKV  directly  enters  the  subcu-
taneous  capillaries  and  infects  susceptible  cells  in the
skin:  macrophages,  fibroblasts  and  endothelial  cells,  where
limited  replication  occurs.40 Locally  produced  viruses  are
transported  to  secondary  lymphoid  organs,  where  it infects
migratory  cells  and release  viruses  to  the lymph  circula-
tion  and  proceed  to  blood.20 Once in the blood,  the  virus
has  access  to  various  parts  of  the body,  including  the  liver,
muscle,  joints  and  brain.41 In  these  tissues,  the  infection  is
associated  with  a marked  infiltration  of mononuclear  cells.
The  mononuclear  cell  infiltration  and  viral replication  in
muscles  and  joints  are associated  with  pain.42,43
CHIKV  infection  elicits  strong  systemic  innate  responses,
principally  involving  the production  of  antiviral  IFN-  as
well  as many  pro-inflammatory  cytokines,  chemokines,  and
growth  factors.44 This  is  followed  by  the  activation  of  the
adaptive  immunity  through  activation  and proliferation  of
CD8+ T  cells  in the  early  stages  of  the  disease.  A classical
switch  to  CD4+ T-cell  response  and the production  of anti-
inflammatory  proteins IL-1RA  and  IL-2RA  are  characteristics
of later  stages  of the  acute  phase.44
CHIKV  infection  induces  a  strong  inflammatory  response
that  is  possibly  orchestrated  by  the  production  of IL-16,
IL-17,  monocyte  chemoattractant  protein  1  (MCP-1),  IP-10,
and  MIP-1. The  end  of  the acute  phase  is  characterized
by  the production  of  proinflammatory  MIF, MIP-1, SDF-
1,  and  IL-6  and  IL-8. CCL5  (RANTES)  levels  were  also
high  in all  patients  during  the first  week  after  symptom
onset.44 CCL5,  MCP-1,  IP-10,  MIP-1, and  IL-8  are produced
by  activated  macrophages  that  are  susceptible  to  CHIKV
infection.40 These  chemokines  play  a  major role  in  leukocyte
recruit  to  sites  of infection,  coordinating  the  deployment  of
efficient  antiviral  defenses.
CHIKV  infection  also  induces  strong  cellular  immune
response.  High plasma  levels  of IFN-,  IL-4,  IL-7,  and  IL-
12p40,  cytokines  that promote  the adaptive  immunity,
suggested  the  involvement  of  cellular responses.44A key  role
for natural  killer  cells  in the clearance  of  infected  cells
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and  in  the  development  of  CHIKV  arthralgia  has  also  been
suggested.45 The  B cell-promoting  cytokines  IL-4  and  in some
cases  IL-10,  were  also  up  regulated  in the first  few  days
after  symptom  onset  probably  initiating  the production  of
CHIKV-specific  IgG.  Additionally,  CD4+ T  lymphocytes,  which
are  also  involved  in the promotion  of  humoral  responses,
were  strongly  activated  toward  the end  of  the acute
phase.44
IgG  antibodies  are  detected  in  the  first  week  after
infection,  indicating  rapid  seroconversion  and  high  levels
of  antibody  responses  among  CHIKV-infected  individuals.46
Specific  IgM  lasts  for  3--4  months  from  the  onset  of  the  dis-
ease,  and  that IgG  lasts  more  than  6 months.47 However,
their  role  in chronic  arthralgia  is  not very  well  understood.
Clinical  manifestations
Chikungunya  fever  is  characterized  by  an abrupt  febrile  ill-
ness,  polyarthralgia  and maculopapular  rash.  The  incubation
period  lasts  2--4  days  (rage  1--12 days) and  asymptomatic
infections  occur  in 5--15% of  the  cases.48
Studies  conducted  in infected  patients  during  La  Réunion
outbreak  indicated  that arthralgia  was  bilateral  and  sym-
metrical  in 78.4%  of  the patients.  It affected  mostly  ankles,
knees,  hands,  wrists,  feet,  shoulders,  and  elbows.49--52 Rash
was  present  in  54%  of  the patients,  predominantly  on  the
trunk  and  arms. Periarticular  edema  was  reported  in 45%
of  the  patients,  affecting  the ankles  in  a  greater  propor-
tion.  Myalgia  and  headache  were  present  in 72  and  63%  of
the  patients,  respectively.  Hemorrhagic  signs such as  gin-
givorrhagia  and  epistaxis  were  only  present  in 10.6%  of  the
patients.49--52
Radiological  findings  are  normal  and  biological  mark-
ers  of  inflammation  like  erythrocyte  sedimentation  rate
and  C-reactive  protein  are  moderately  elevated.49,50,52--54
Iridocyclitis  and retinitis  are  the  most  common  ocular  man-
ifestations  associated  with  CHIKV  infection  and have a
benign  course  with  complete  resolution  and  preservation  of
vision.55
The  acute  signs  and  symptoms  usually  resolve  in less
than  2 weeks,  but  arthralgia  may  last  for weeks,  months
or  even  years;56,57 this is  a clinical  symptom  that  may  distin-
guish  CHIKV  from  dengue  virus  infection.  Also  in a univariate
analysis,  CHIKV  infected  patients  displayed  fewer  gastroin-
testinal  symptoms  compared  to  dengue-infected  patients,
and  a  higher  proportion  of  myalgia  and arthralgia.58
Chikungunya  is  not  generally  considered  life  threaten-
ing;  nevertheless  severe  forms  can  also  be  present.  Patients
with  severe  chikungunya  fever  requiring  hospitalization  tend
to  be  older  and  have  comorbidities  such  as  cardiovascu-
lar,  neurologic,  and respiratory  disorders  or  diabetes,  which
are  independent  risk  factors  for  severe  disease.49,59 Severe
chikungunya  can  manifest  as  encephalopathy  and encephali-
tis,  myocarditis,  hepatitis,  and  multiorgan  failure.  These
rare  forms  can  be  fatal  and  typically  arise  in patients  with
underlying  medical  conditions.60,61 Neonates  are also  at risk
for  severe  infection  associated  with  neurologic  signs.  The
rate  of  infection  of  neonates  born  to  viremic  mothers  and
exposed  to the virus  during birth can  reach  50%,  leading  to
severe  disease  and  encephalopathy,  resulting  in  long-term
neurological  sequelae  and  poor  outcome.62
In  general,  CHIKV  infection  has  a good  prognosis.  Nev-
ertheless,  older  patients  (<45  years  old)  are  more  likely
to  evolve  toward  relapsing  and lingering  chronic  rheumatic
musculoskeletal  pain.63 A  study  showed that  subjects  who
experienced  severe  initial  rheumatic  involvement  (six  or
more  painful sites  with  at least  four other  symptoms)  at the
acute  stage of infection  were  more  likely  to  exhibit  chronic
rheumatic  musculoskeletal  pain  on  follow  up.63 Moreover,
a  positive  association  between  high  titers  of CHIKV-specific
IgG  in the  plateau  phase  and  long-lasting  arthralgia  has  been
observed  contemporaneously  from  a pilot study  and  in the
Italian  cohort.63,64 A possible  mechanistic  hypothesis  may  be
that  an  imbalance  toward  B cell  expansion  and  differentia-
tion,  in response  to  IL-6  secretion  following  the  progression
of  both  immunosenescence65 and chikungunya  is  triggered
by  viral  persistence  in host  sanctuaries.66,67
Taking  in  consideration  the clinical  features  mentioned
above,  the algorithm  presented  in Fig.  2 would  guide the
clinician  throughout  case  definition,  and management.  This
algorithm  is  an  adaptation  from  Palacios-Martinez.68
Diagnosis
Chikungunya  infection  is  diagnosed  on  the basis  of  clini-
cal,  epidemiological  and  laboratory  criteria.  An  acute  onset
of  fever  and  severe  arthralgia  or  arthritis  that  is  not
explained  by  other  medical  disorders  is  considered  a  pos-
sible  CHIKV  case.20Three  main  types  of  laboratory  tests
are  used for  diagnosing  CHIKV  infection:  virus  isolation,
reverse  transcriptase-polymerase  chain  reaction  (RT-PCR),
and  serology.
Virus  isolation  can be performed  on field  collected
mosquitoes  or  acute  serum  specimens  (≤8  days).  Serum
obtained  from  whole  blood  collected  during  the first week  of
illness  can  be inoculated  into  a susceptible  cell  line  or  suck-
ling  mouse  at  a reference  laboratory.  This  can be  achieved
if  the sample  is  transported  cold  (between  2 ◦C  and 8 ◦C  or
dry  ice)  and  as  soon  as  possible  (within  48  h).69
Several  RT-PCR  assays  for  the detection  of  CHIKV  RNA
have  been  published.  Real-time,  closed  system  assays  should
be  used,  due  to their  increased  sensitivity  and lower  risk
of  contamination.  Taking  into  account  the sensitivity,  PAHO
recommends  the use  of  the  CHIKV  RT-PCR  protocols  from  the
Centers  for  Disease  Control  and  Prevention  and the Institute
Pasteur.14,70 Serum  from  whole  blood  is  used  for PCR  testing
as  well  as  virus  isolation.
For  serological  diagnosis,  serum  obtained  from  whole
blood  is used  in enzyme-linked  immunosorbent  assay
(ELISA).  The  serum  (or  blood)  specimen  should be  trans-
ported  at  2--8 ◦C  and  should  not be frozen.  Serologic
diagnosis  can  be made  by  demonstration  of IgM antibodies
specific for  CHIKV  or  by  a  four-fold  rise  in IgG  titer  in acute
and  convalescent  specimens.69
The  determination  of IgM  can  be  made by  different  com-
mercially  available  techniques.  However,  it should  be  taken
into  account  that  the best  sensitivity  is  from  techniques  that
use  the complete  virus  as  antigen  compared  to  those  that use
recombinant  proteins.  Since  the first  commercially  available
kits  had  poor results,  it  is  recommended  that in house  tech-
niques  for  IgM/IgG  ELISA  be  implemented  using  the purified
viral  antigen  and  following  the  CDC  protocols.60 Recent  ELISA
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Clinical criteria
Acute onset of fever
> 38,5°C and severe
arthralgia/arthritis not
explained by other
medical conditions.
Residing or having visited
epidemic areas, having
reported transmission within
15 days prior to the onset of
symptoms.
Epidemiological criteria
Viral isolation
Presence of viral ARN
Presence of specific lgM/lgG
antibodies
Four fold increase of antibodies in
two samples separated by 14 days.
Laboratory criteria
•
•
•
•
CHIKV fever clinical suspicion
Emergency department admission
Vital signs measurement hourly
Supportive treatment
•
•
Hospital care
Yes
Yes
No
Asses
No
NoYesTransfer to third
level hospital
Atypical
manifestations or
severity signs
Dengue or malaria
warning signs
Hemodynamic instability
Postural dizziness, cold
extremities
Decreased urine output
Any bleeding under the skin or
through any orifice
Incessant vomiting
Pregnancy
Patients above 60 years old or
newborns
•
•
•
•
•
•
•
Symptomatic treatment:
Acetaminophen until other etiologies, like
dengue, are ruled out.
•
Non-steroidal anti-inflammatory drugs or
narcotics can be used if acetaminophen
does not provide relief.
•
Observation•
Asses evolution•
Observation•
Asses evolution•
Hemodynamic status and hydration•
Renal failure, neurologic alterations,
hepatic failure
•
Suspected case
Clinical criteria: +
Epidemiological criteria: +
Laboratory criteria: -
Primary attention or
ambulatory care
Immediate notification
to ministry of health
Confirmed case
Clinical criteria: +
Epidemiological criteria: +/-
Laboratory criteria: +
Figure  2  CHIKV  infection  diagnostic  and  therapeutic  algorithm.
Adapted  from  Palacios-Martinez.63
Table  1  Accuracies  and  sensitivities  of  different  chikungunya  fever  diagnostic  assays.
Assay  Sensibility  (%)  Specificity  (%)  PPV  (%)  NPV  (%)
RT-PCR  88.5  100  100 97.5
Standard Diagnostics  Chikungunya  IgM  ELISA  3.9 92.5  10  81.6
Novatech Chikungunya  IgM Capture  ELISA  76.9  91.9  100 97.5
Novatech Chikungunya  IgG  Capture  ELISA  80  100  100 95.6
Source:  Modified and adapted from Blacksell.71,89--91
PPV, positive predictive value; NPV, negative predictive value; RT-PCR, reverse transcriptase-polymerase reaction; IgM, immunoglobulin
M; IgG, Immunoglobulin G; ELISA, enzyme-linked immunosorbent assay.
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assays  have  improved  sensibility  and  specificity  as  shown  in
Table  1.71 The  use  of rapid tests  is  not recommended.  The
second  sample  for  serological  determination  should be taken
between  1 and 2 weeks  after the first  sample.  Seroconver-
sion  can  also  be  detected  as  an  increase  in IgG by  a  factor
of  4  or  more  between  acute-phase  and  convalescent-phase
serum  samples.69
Treatment
There  is  no  specific  antiviral  drug treatment  for  CHIKV
infection.  Symptomatic  treatment  is  recommended  after
excluding  more  serious  conditions  like malaria,  dengue,  and
bacterial  infections.20,21
In acute  infection,  treatment  is  symptomatic  and  sup-
portive,  comprised  of  rest  and the use  of  acetaminophen
to  relieve  fever  (<4 g/day).  The  use  of  ibuprofen,  naproxen,
or  another  non-steroidal  anti-inflammatory  agent  (NSAID)  to
relieve  the  arthritic  component  of  the  disease  can  be used
when  dengue  infection  is  discarded.60 In patients  with  severe
joint  pains  that  are not relieved  by  NSAID, tramadol  or  nar-
cotics  (e.g.,  morphine)  can  be  advised.60,61 Patients  should
be  advised  to  drink  plenty  of  fluids  to  replenish  fluid  lost
from  sweating,  vomiting,  and other  insensible  losses.60,72
While  recovery  from  CHIK  is  the expected  outcome,
convalescence  can  be  prolonged  and  persistent  joint
pain  may  require  pain  management,  including  long-term
anti-inflammatory  therapy.  Specific  treatment  for  diffuse
post-CHIKV  polyarthralgia  in chronic  stage  consists  of oral
or topic  NSAIDs  plus  a  short  course  of oral  corticotherapy  or
corticoid  injection  in affected  joint.  Neuropathic  pain  can
treated  with  tricyclic  antidepressants,  antiepileptic  drugs  or
tramadol.73
Although  an older  study  suggested  that  hydroxychloro-
quine  phosphate  offered  some  benefit  in arthralgia,74
posterior  studies  failed  to  confirm  its  efficacy.73,75,76
In patients  with  refractory  joint  symptoms,  alternative
therapies  such  as  methotrexate  (MTX)  can  be  evaluated.  In
a  retrospective  study  made in La  Réunion  Island,  54  out of
72  patients  had  a positive  clinical  response  when treated
with  MTX.73,77 When  MTX  is  contraindicated  or  ineffective,
immune-modulating  biologic  agents  as  etanercept,  ritux-
imab,  or  tocilizumab  can  be  used.73
It  has  been  shown  that  patients  with  rheumatoid  arthri-
tis  have  low  vitamin  D  levels  and  a  negative  correlation  with
disease  activity.78 Therefore,  reposition  of  vitamin  D could
improve  disease  severity.  In a  study  made  in India,  patients
with  chronic  CHIKV-related  arthritis  were  treated  with  vita-
min  D  and  calcium  for  five  months  which  improved  joint  pain
and  fatigue.79
In addition  to  pharmacotherapy,  cases  with  arthralgia
and  joint  stiffness  may  benefit  from  a program  of grad-
uated  physiotherapy  in acute  and  chronic  stages  of  the
disease.  Movement  and  mild  exercise  tend  to improve  morn-
ing  stiffness  and  pain,  but  heavy  exercise  may  exacerbate
symptoms.
Prevention
Pending  vaccine  development,  the  only  effective  preventive
measures  consist  of  individual  protection  against  mosquito
bites  and  vector control.  Control  of  both  adult  and  larval
mosquito  populations  uses  the same  model  as  for dengue
and  has  been  relatively  effective  in many  countries  and
settings.80 Mosquito  control  is  the  best available  method
for  preventing  CHIKV  infection.  Breeding  sites  must  be
removed,  destroyed,  frequently  emptied,  and  cleaned  or
treated  with  insecticides.3
For  protection,  clothing  which  minimizes  skin  exposure
to  the day-biting  vectors  is  advised.  Repellents  can be
applied  to  exposed  skin  or  to  clothing  in strict  accor-
dance  with  product  label  instructions.  Repellents  should
contain  DEET  (N,N-diethyl-3-methylbenzamide),  IR3535  (3-
[N-acetyl-N-butyl]-aminopropionic  acid  ethyl  ester)  or
icaridin  (1-piperidinecarboxylic  acid, 2-(2-hydroxyethyl)-
1-methylpropylester).  Mosquito  coils  or  other  insecticide
vaporizers  may  also  reduce  indoor  biting.3
Vaccines
There  is  currently  no  commercial  vaccine  for CHIKV,
although  some  candidate  vaccines  have  been  tested  in
human  beings.81,82
Several  technologies  have  been  used  to  develop  CHIK  vac-
cines,  including  inactivated  viral vaccines,  live-attenuated
viruses,  alphavirus  chimeras,  recombinant  viral  vaccines,
consensus-based  DNA vaccines,  recombinant  subunit  vac-
cines  and more  recently,  a virus-like  particle  (VLP)  vaccine.
Two  vaccine  candidates  have  finished  phase  I trials:  a
live  recombinant  measles-virus-based  chikungunya  vaccine
and  the  VRC-CHKVLP059-00-VP,  VLP vaccine.  The  live  recom-
binant  measles-virus-based  chikungunya  vaccine  had  good
immunogenicity,  even  in the presence  of  measles  immu-
nity,  was  safe,  and  had  a generally  acceptable  tolerability
profile.83 The  VLP  vaccine,  VRC-CHKVLP059-00-VP  was  also
immunogenic,  safe,  and well  tolerated.84
Economic burden
In India,  the chikungunya  epidemic  in  2006  imposed  heavy
epidemiological  burden  and  productivity  loss  to  the  commu-
nity.  National  burden  of chikungunya  was  estimated  to  be
25,588  DALYs  lost during  2006  epidemic.  Persistent  arthral-
gia  was  found  to  impose  heavy  burden,  accounting  for  69%
of  the total  DALYs.  The  productivity  loss  in terms  of  income
foregone  was  estimated  to  be a minimum  of  6  million
USD.85 Other  studies  made  in  India  reported  that  the burden
for  Andhra  Pradesh  was  6600  DALYs  (cost:  US$12,400,000).
While  the  burden  was  moderate,  costs  were  high  and  mostly
out  of pocket.86
A study  made  with  military  policemen  at La  Réunion  in
June  2006  reported  that  most  symptomatic  patients  (93.7%)
complained  of  a  chronic  stage  of  the disease,  which is  char-
acterized  by  pains  in joints  or  bones,  or  both,  although  the
inquiry  was  made  6  months  after  the  epidemic  peak.  Most
working  adults  are  disabled  with  loss  of mobility,  hand  dis-
ability,  and  depressive  reaction,  which  can each  last  for
weeks  to  months  and  has negative  consequences  in health,
social  organization,  and  economy  in epidemic  areas.87,88
With  these  antecedents,  if the outbreak  spreads
throughout  Mexico,  the infected  working  adults  will  be  inca-
pacitated,  and  will  increase  the economic  burden.
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Conclusion
The  arrival  of  CHIKV  to  America  will  be  a challenge  to  the
public  health  system  and a  significant  economic  burden.  The
probability  of autochthonous  transmission  in  the  rest  of  Mex-
ico  and  USA  is  high  due  to  the vector  ubiquity.  Economic
development  does  not  protect  countries  from  vector-borne
diseases;  modern  lifestyles  may  amplify  an epidemic  through
travel,  population  aging,  and production  of  solid  waste  that
can  shelter  Aedes mosquitoes.
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